Omega-3 Quality & Dose

Omega-3 is not one molecule, one dose, or one trial — it is EPA, DHA, and a fifteen-year argument about who actually benefits. This page decodes labels, distinguishes EFSA’s European 250 mg/day Adequate Intake from condition-specific trial and prescription doses up to 4 g/day, and explains why no universal U.S. general-use dose is established.

The Two Molecules That Matter

"Omega-3" is shorthand for a family, and only two members carry the marine-fats evidence: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). EPA is the molecule most tied to vascular and anti-inflammatory signaling; DHA is a structural component of brain and retinal tissue. The plant omega-3, alpha-linolenic acid (ALA) from flax, chia, and walnuts, is genuinely healthy — but the body converts only a small share of it to EPA and less to DHA. The conversion review by Plourde & Cunnane (Applied Physiology, Nutrition, and Metabolism, 2007) put the EPA yield in single-digit percentages for most adults, somewhat higher in some women, and the DHA yield near zero for many. The practical reading: flaxseed is not a substitute for marine omega-3, and plant-based eaters who want the long-chain fats use algal oil.

What the Label Hides

The single most useful skill in this aisle is reading past the front label to the supplement-facts panel. A softgel labeled "1,000 mg fish oil" typically delivers around 300 mg of combined EPA+DHA — 180 mg EPA and 120 mg DHA — because most of the oil is other fatty acids. That is a 30% potency product, and it means the common advice "take 1 gram of omega-3" requires three or four standard softgels, not one. To hit 1,000 mg of actual EPA+DHA you buy a concentrated product or accept a larger softgel count. The math is always the same: add the EPA and DHA lines on the label, divide by the serving size, and price the result per gram of the molecules you are actually buying.

Dose by Goal

The right dose is set by the goal, not by the bottle. The ladder below reflects the trial literature, and the top rungs are clinician territory.

The triglyceride rung is well documented: the American Heart Association's science advisory (Circulation, 2019) notes that 2–4 g/day of EPA+DHA lowers triglycerides by roughly 20–30% in patients with elevated levels — an effect size that shrinks in people whose triglycerides are normal to begin with. Those doses can raise bleeding tendency, which is why they are supervised, prescription-adjacent territory rather than a grocery-aisle default.

The Trial Rollercoaster

Fifteen years of trials produced what looks like whiplash until you sort it by population and dose:

• 1999 · GISSI-Prevenzione (Lancet) — 11,324 people after a heart attack, ~850 mg/day for 3.5 years: about 15% fewer major events in the four-way analysis, with the largest effect on sudden death. The trial that launched the capsule era.
• 2018 · ASCEND (NEJM) — 15,480 adults with diabetes, 1 g/day for 7.4 years: no significant effect on serious vascular events. First big null.
• 2019 · REDUCE-IT (NEJM) — 8,179 high-risk statin users with triglycerides of 135–499 mg/dL, 4 g/day of purified icosapent ethyl: major cardiovascular events fell from 22.0% to 17.2% — a 25% relative reduction. The dose-and-population lesson.
• 2019 · VITAL (NEJM) — 25,871 generally healthy adults, 840 mg/day: no effect on the primary composite, but total heart attacks fell by 28%, concentrated in people with low fish intake — a subgroup finding that generates hypotheses rather than setting a general dose.
• 2020 · STRENGTH (JAMA) — 13,078 similar high-risk patients, 4 g/day of a mixed EPA+DHA formulation: stopped early for futility. The plot twist.

The meta-analytic average lands on the honest middle: Aung and colleagues (JAMA Cardiology, 2018) pooled ten trials and 77,917 participants and found no significant overall association between omega-3 supplementation and coronary heart disease or major vascular events. The pattern behind the whiplash: benefits track baseline intake, risk level, and dose — not the molecule's reputation.

The Mineral-Oil Debate

REDUCE-IT and STRENGTH looked like a clean experiment — same 4 g dose, same kind of patients, opposite results — but they differed in a hidden variable: the placebo. REDUCE-IT used mineral oil, and critics argue mineral oil may have slightly worsened the control group's risk markers, inflating the apparent benefit of icosapent ethyl. STRENGTH used corn oil and found nothing. The honest reading is that the two trials cannot settle whether pure EPA is superior to EPA+DHA: the difference may owe more to the placebo than to the molecule. What survives the debate is narrower and solid — 4 g of icosapent ethyl reduced events in that specific high-risk population, and the general-purpose capsule evidence remains modest at best.

Fish vs Pill

The food-first hierarchy is unusually clear here. Two oily-fish servings per week — salmon, mackerel, sardines, herring — deliver roughly 1.7 to 2 grams of EPA+DHA along with protein, selenium, and vitamin D, and the observational literature associates that pattern with substantially lower coronary death risk (Mozaffarian & Rimm, JAMA, 2006). For most adults the mercury arithmetic favors fish: the cardiovascular benefit outweighs contaminant risk, with specific guidance reserved for pregnancy. A capsule may be an option for people who do not eat fish, but VITAL’s low-intake finding was exploratory and does not show that capsules reliably provide the greatest benefit in this group. The chart shows why food is the better buy:

Buying Rules

• 💵 Price by EPA+DHA, not by bottle — divide the price by the grams of EPA+DHA per serving, not by the softgel count or the front-label milligrams.
• 🔎 Look for third-party testing — IFOS, USP, or NSF verification is the practical defense against oxidized or mislabeled oil, since freshness is not visible on a shelf.
• 👃 Trust the nose — a fishy or bitter smell means oxidation, and oxidized oil is worse than none; refrigerate liquid forms and avoid bulk bottles you cannot finish while fresh.
• 🌱 Plant-based route — algal oil supplies EPA and DHA directly, which sidesteps the ALA conversion ceiling entirely.

Questions, Answered Briefly

• 🐟 Fish or capsules? Fish when you can — the food delivers co-factors and the strongest observational support. The capsule is the evidence-backed fallback for people who rarely eat fish — though VITAL’s low-intake finding was a subgroup signal that does not establish a routine dose or prove that people who rarely eat fish benefit most from supplements.
• 💊 How do I read a label in ten seconds? Add the EPA and DHA lines on the supplement-facts panel. That sum is your real dose; the "1,000 mg fish oil" headline number is not.
• 🔥 What about rancidity? Oxidized fish oil is a real quality problem and a reason to favor third-party-tested, smaller, fresher bottles — and to trust a bad smell.
• 🌱 Is flaxseed enough? Not as a marine omega-3 substitute — ALA converts poorly to EPA and barely to DHA. Plant-based eaters use algal oil for the long-chain fats.

Related Topics